Treatment Response Imaging in Prostate Cancer

被引：0

作者：

Swiha, Mina ^{[1
,2
]}

Gafita, Andrei ^{[3
]}

Nguyen, Andrew ^{[1
,4
]}

Emmett, Louise ^{[1
,4
,5
]}

机构：

[1] St Vincents Hosp, Dept Theranost & Nucl Med, Sydney, Australia

[2] Univ Western Ontario, Dept Med Imaging, Nucl Med Div, London, ON, Canada

[3] Johns Hopkins Med, Russell H Morgan Dept Radiol & Radiol Sci, Nucl Med & Mol Imaging Div, Baltimore, MD USA

[4] Univ New South Wales, St Vincents Clin Sch, Sydney, Australia

[5] Garvan Inst Med Res, Sydney, Australia

来源：

PET CLINICS | 2024年 / 19卷 / 03期

关键词：

Prostate cancer; PSMA-PET; PSMA-SPECT; 177Lu-PSMA; Treatment response; PSMA-PET; RADIOLIGAND THERAPY; OPEN-LABEL; CRITERIA; MITOXANTRONE; CABAZITAXEL; TOMOGRAPHY; PREDNISONE; RECIST;

D O I：

10.1016/j.cpet.2024.03.009

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Posttherapy imaging is a crucial tool for response assessment to both local and systemic therapies in early stage and late -stage PCa, with conventional imaging (diagnostic CT and bone scan) currently remaining standard of care. PSMA PET/ CT, an innovative molecular imaging tool, has shown potential in response assessment in PCa, but more research is required to validate it for clinical use. PSMA SPECT/CT is a potential costeffective alternative to PSMA PET/CT in assessment of response to PSMA-targeted radionuclide therapy that also warrants further evaluation. 18 F- FDG-PET/CT have a complementary role in nonPSMA-avid disease.

引用

页码：417 / 430

页数：14

共 51 条

[11] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Eisenhauer, E. A.
Therasse, P.
Bogaerts, J.
Schwartz, L. H.
Sargent, D.
Ford, R.
Dancey, J.
Arbuck, S.
Gwyther, S.
Mooney, M.
Rubinstein, L.
Shankar, L.
Dodd, L.
Kaplan, R.
Lacombe, D.
Verweij, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
[12] Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)
Emmett, Louise
John, Nikeith
Pathmanandavel, Sarennya
Counter, William
Ayers, Maria
Sharma, Shikha
Agrawal, Shikha
Poole, Aron
Hovey, Elizabeth
Pranavan, Ganes
Gedye, Craig
Mallesara, Girish
Guminski, Alex
Lee, Adrian
Stockler, Martin R.
Hickey, Adam
Eu, Peter
Joshua, Anthony M.
Crumbaker, Megan
Nguyen, Andrew
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[13] 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
Emmett, Louise
Tang, Reuben
Nandurkar, Rohan
Hruby, George
Roach, Paul
Watts, Jo Anne
Cusick, Thomas
Kneebone, Andrew
Ho, Bao
Chan, Lyn
van Leeuwen, Pim J.
Scheltema, Matthijs J.
Nguyen, Andrew
Yin, Charlotte
Scott, Andrew
Tang, Colin
McCarthy, Michael
Fullard, Karen
Roberts, Matthew
Francis, Roslyn
Stricker, Phillip
[J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (06) : 866 - 872
[14] Emmett L, 2018, J NUCL MED, V59
[15] Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
Evans, Michael J.
Smith-Jones, Peter M.
Wongvipat, John
Navarro, Vincent
Kim, Sae
Bander, Neil H.
Larson, Steven M.
Sawyers, Charles L.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (23) : 9578 - 9582
[16] EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy
Fanti, Stefano
Briganti, Alberto
Emmett, Louise
Fizazi, Karim
Gillessen, Silke
Goffin, Karolien
Hadaschik, Boris A.
Herrmann, Ken
Kunikowska, Jolanta
Maurer, Tobias
MacLennan, Steven
Mottet, Nicolas
Murphy, Declan G.
Oprea-Lager, Daniela E.
O'Sullivan, Joe M.
Oyen, Wim J. G.
Rouviere, Olivier
Sartor, Oliver
Stenzl, Arnulf
Van Poppel, Hendrik
Walz, Jochen
Witjes, Wim
Bjartell, Anders
[J]. EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 530 - 536
[17] Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Fanti, Stefano
Goffin, Karolien
Hadaschik, Boris A.
Herrmann, Ken
Maurer, Tobias
MacLennan, Steven
Oprea-Lager, Daniela E.
Oyen, Wim J. G.
Rouviere, Olivier
Mottet, Nicolas
Bjartell, Anders
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (02) : 469 - 476
[18] Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria
Fanti, Stefano
Hadaschik, Boris
Herrmann, Ken
[J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (05) : 678 - 682
[19] Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Fendler, Wolfgang P.
Calais, Jeremie
Eiber, Matthias
Flavell, Robert R.
Mishoe, Ashley
Feng, Felix Y.
Nguyen, Hao G.
Reiter, Robert E.
Rettig, Matthew B.
Okamoto, Shozo
Emmett, Louise
Zacho, Helle D.
Ilhan, Harun
Wetter, Axel
Rischpler, Christoph
Schoder, Heiko
Burger, Irene A.
Gartmann, Jeannine
Smith, Raven
Small, Eric J.
Slavik, Roger
Carroll, Peter R.
Herrmann, Ken
Czernin, Johannes
Hope, Thomas A.
[J]. JAMA ONCOLOGY, 2019, 5 (06) : 856 - 863
[20] Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer
Gafita, Andrei
Djaileb, Loic
Rauscher, Isabel
Fendler, Wolfgang P.
Hadaschik, Boris
Rowe, Steven P.
Herrmann, Ken
Calais, Jeremie
Rettig, Matthew
Eiber, Matthias
Weber, Manuel
Benz, Matthias R.
Farolfi, Andrea
[J]. RADIOLOGY, 2023, 308 (01)

← 1 2 3 4 5 6 →